Research Article Volume 01, Issue No. 02. 2025

THE JOURNAL OF MEDICAL RESEARCH AND APPLIED SCIENCE



Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection

[1] Subiyanto, [1] Grace

[1] Faculty of Medicine, Padjadjaran University, Bandung City, West Java, Indonesia

Correspondence : dr.subiyanto382@gmail.com

Article History :
Received date : 2024/10/04
Revised date : 2024/11/12
Accepted date : 2024/12/29
Published date : 2025/01/12

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The association between gastric acid suppression, particularly through the use of proton pump inhibitors (PPIs), and recurrent Clostridium difficile infection (CDI) has garnered significant attention in the medical literature over the past decade. The body of research surrounding this topic reveals a complex interplay between acid suppression therapies and the risk of CDI, with various studies contributing critical insights that enhance our understanding of this public health concern. **Literature Review:** Research conducted by (Jaynes & B. Kumar, 2018) and (Kachrimanidou & Tsintarakis, 2020) further elucidates the impact of PPIs on gut microbiota, revealing that long-term use can diminish microbial diversity, thereby reducing colonization resistance against C. difficile and increasing susceptibility to recurrent infections. Conversely, some articles, such as the one by (Novack et al., 2014), challenge the direct causality between PPI use and CDI risk, suggesting that observational studies may be biased and that confounding factors, particularly antibiotic use, should not be overlooked in this context. The implications of PPI use extend beyond infection risk; studies like that of (Stuart Bradley et al., 2019) indicate that PPI exposure may also influence mortality rates among elderly patients post-CDI treatment, further complicating the clinical landscape. **Conclusion :** In conclusion, the literature collectively underscores the critical need for healthcare providers to carefully weigh the benefits of PPI therapy against the potential risks of CDI, particularly in populations at heightened risk. The association between gastric acid suppression and CDI is complex, necessitating further research to elucidate the underlying mechanisms and to develop informed prescribing practices.

Keyword: Association, Gastric Acid Suppression, Recurrent Clostridium difficile Infection

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The association between gastric acid suppression, particularly through the use of proton pump inhibitors (PPIs), and recurrent Clostridium difficile infection (CDI) has garnered significant attention in the medical literature over the past decade. The body of research surrounding this topic reveals a complex interplay between acid suppression therapies and the risk of CDI, with various studies contributing critical insights that enhance our understanding of this public health concern.

In a systematic review and meta-analysis by (M. Tleyjeh et al., 2012), the authors highlighted the growing use of PPIs and their potential role in facilitating CDI by altering the acidic environment of the stomach. This review noted the increasing incidence and mortality of CDI, attributing these trends to factors such as an aging population and heightened antibiotic use, alongside the prescription of acid-suppressive medications. The authors underscored the necessity of evaluating the implications of PPI use in relation to CDI, utilizing the GRADE framework to assess their findings.

(Patil & Blankenship, 2013) further elaborated on the overprescription of PPIs, emphasizing their effectiveness as acid suppressive agents while cautioning against their potential to increase CDI risk among hospitalized patients. They posited that gastric acid serves as a barrier to the germination of C. difficile spores, suggesting that the use of PPIs may inadvertently promote the growth of this pathogen. However, they acknowledged the need for further research to elucidate the mechanisms by which PPIs may affect CDI risk.

Contrasting these findings, (Novack et al., 2014) presented a critical perspective on the association between gastric acid suppression and CDI. Their analysis suggested that while PPIs are indeed a risk factor for CDI, the relationship may be influenced by biases inherent in observational studies. They called for a more nuanced understanding of the factors contributing to CDI, urging caution in attributing causality solely to PPI use.

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

In a subsequent study, (Weiss et al., 2015) examined the effects of PPIs and histamine-2 receptor antagonists on treatment outcomes for CDI, revealing that prolonged use of PPIs could diminish microbial diversity, thereby increasing susceptibility to CDI. This research underscored the potential for acid suppression to disrupt gut microbiota, which is critical for maintaining a balanced intestinal environment.

(Jaynes & B. Kumar, 2018) expanded on the implications of long-term PPI use, indicating that it may alter the colonic microbiome, thereby reducing colonization resistance against C. difficile. Their findings highlighted a consistent decrease in microbial diversity among patients on PPIs, which could facilitate the proliferation of C. difficile and contribute to recurrent infections.

(Stuart Bradley et al., 2019) focused on the impact of PPI exposure on mortality rates among elderly patients post-CDI treatment. This study drew attention to the significant economic burden of CDI and the need to assess the role of PPIs in influencing clinical outcomes, particularly among vulnerable populations.

(Kachrimanidou & Tsintarakis, 2020) provided insights into how PPIs may disrupt the gut microbiota, emphasizing the alteration in the Firmicutes to Bacteroidetes ratio as a potential risk factor for CDI development. They noted that patients with underlying gastrointestinal conditions, such as inflammatory bowel disease, may face heightened risks associated with CDI.

Most recently, (Huang et al., 2024) conducted a systematic review and meta-analysis that reaffirmed the association between PPI use and CDI risk, emphasizing the importance of duration of use in hospitalized patients. Their findings contribute to the growing body of evidence suggesting that both PPIs and H2-receptor antagonists may increase susceptibility to CDI.

Collectively, these studies illustrate the intricate relationship between gastric acid suppression and CDI, highlighting the potential risks associated with PPI therapy. The literature underscores the need for careful consideration of PPI use, particularly in populations at risk for CDI, and calls for further research to clarify the mechanisms underlying these associations.

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

LITERATURE REVIEW

The article "Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis" by (M. Tleyjeh et al., 2012) provides a comprehensive examination of the relationship between proton pump inhibitors (PPIs) and Clostridium difficile infection (CDI). The authors present a systematic review and meta-analysis that critically assesses the existing literature on this topic, highlighting the growing concern surrounding the overprescription of PPIs and their potential role as a risk factor for CDI.

The article begins by contextualizing the widespread use of PPIs, which are among the most commonly prescribed medications globally. The authors note that despite their therapeutic benefits, there is increasing evidence suggesting that PPIs may contribute to the risk of enteric infections, particularly CDI. This is particularly relevant given the rising incidence of CDI, which has been linked to various factors including an aging population and increased antibiotic use (M. Tleyjeh et al., 2012). The authors emphasize the importance of understanding the implications of gastric acid suppression therapy in the context of CDI, as this infection has emerged as a significant public health challenge.

One of the key contributions of this article is its synthesis of data from multiple studies to evaluate the association between PPI use and CDI. The authors reference four recent meta-analyses that collectively suggest a correlation between PPI therapy and an increased risk of CDI. This evidence is critical, as it underscores the need for healthcare providers to carefully consider the risks associated with PPI therapy, particularly in populations that may already be at heightened risk for CDI.

The article also discusses the recent warnings issued by the United States Food and Drug Administration (FDA) regarding the potential link between CDI and PPI use. This regulatory perspective adds an additional layer of significance to the findings, as it reflects a growing recognition of the serious implications of gastric acid suppression on gastrointestinal health.

The article "Proton Pump Inhibitors and Clostridium Difficile Infection: Are We Propagating an Already Rapidly Growing Healthcare Problem?" by (Patil &

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Blankenship, 2013) provides a critical examination of the relationship between proton pump inhibitors (PPIs) and the incidence of Clostridium difficile infection (CDI). The authors articulate a compelling argument regarding the overprescription of PPIs and their potential role in exacerbating CDI, particularly in hospitalized patients.

A central theme of the article is the protective role of gastric acid in inhibiting the germination of C. difficile spores and limiting the survival of the bacteria. The authors discuss how PPIs, by significantly reducing gastric acidity, may facilitate the passage of vegetative C. difficile into the small intestine, thereby increasing the risk of CDI. This hypothesis is supported by recent studies indicating a correlation between PPI use and the development of Clostridium difficile-associated diarrhea (CDAD) (Patil & Blankenship, 2013).

However, the article also highlights an important nuance in understanding this relationship. While the authors acknowledge that C. difficile spores are resistant to normal gastric pH levels, they raise questions about the broader implications of PPI use on the gut microbiome and host immune responses. Specifically, the inhibition of the phagocytic neutrophil response to pathogens such as Escherichia coli by PPIs suggests that these medications may alter host defenses, potentially increasing the susceptibility to CDI (Patil & Blankenship, 2013).

The authors call for further research to elucidate the mechanisms by which PPIs may influence the risk of CDI, particularly regarding their impact on the normal flora of the gastrointestinal tract. This aspect is critical, as understanding whether PPIs have a significant effect on the gut microbiome could inform clinical practices and guidelines for the use of acid-suppressive therapies.

The article "Acid Suppression Therapy Does Not Predispose to Clostridium difficile Infection: The Case of the Potential Bias" by (Novack et al., 2014) provides a critical examination of the association between proton pump inhibitor (PPI) therapy and the incidence of Clostridium difficile infection (CDI). The authors argue against the prevailing notion that iatrogenic gastric acid suppression significantly increases the risk of CDI, particularly in nosocomial settings.

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article begins by addressing the common hypothesis that gastric acid suppression via PPIs creates a more favorable environment for the proliferation of Clostridium difficile. (Novack et al., 2014) systematically review existing literature, highlighting a potential bias in studies that report a correlation between PPI use and CDI. They emphasize that while some studies suggest a relationship, many fail to adequately control for confounding factors, such as the underlying health conditions of patients who are prescribed PPIs. This critical point raises questions about the validity of the conclusions drawn in those studies.

Furthermore, the authors discuss the role of other medication risk factors, particularly antibiotics, which are well-established contributors to the development of CDI. They argue that the focus on PPIs as a primary risk factor may detract from the broader context of antibiotic use and its implications for gut microbiota and infection risk. The article also presents evidence indicating that gastric acid suppression does not necessarily promote Clostridial diarrhoea in elderly populations, who are often the most affected by CDI.

In their analysis, (Novack et al., 2014) effectively synthesize findings from various studies, reinforcing the argument that while PPIs may alter gastrointestinal flora, attributing increased CDI risk solely to acid suppression overlooks critical variables. They call for a more nuanced understanding of the interplay between gastric acid suppression, antibiotic use, and the susceptibility to CDI.

The article titled "Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea" by (Weiss et al., 2015) provides an in-depth examination of the relationship between gastric acid suppression through proton pump inhibitors (PPIs) and the risk of Clostridium difficile (C. difficile) infection. The authors present compelling evidence suggesting that the use of PPIs not only increases the susceptibility to C. difficile-associated diarrhea but also correlates with the severity of the disease and the likelihood of recurrent infections.

One of the key insights from the article is the identification of iatrogenic gastric acid suppression as a significant risk factor for nosocomial C. difficile infections. The authors detail how prolonged PPI use can lead to a reduction in

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

microbial diversity within the gut, thereby creating an environment conducive to C. difficile colonization and subsequent infection. This finding is particularly relevant in clinical settings where patients are frequently prescribed PPIs for various gastrointestinal disorders, highlighting the need for careful consideration of the risks associated with their use.

Furthermore, the article discusses the differential risk associated with PPI use relative to levels of antibiotic exposure. This nuanced view underscores the complexity of interactions between gastric acid suppression, antibiotic therapy, and the gut microbiome, suggesting that patients with higher antibiotic exposure while on PPIs may face an elevated risk of developing C. difficile infections. The authors also emphasize the importance of a systematic review to better understand the risk factors for enteric infections in patients undergoing acid suppression therapy.

The implications of this research are significant, as they call for a reassessment of the routine use of PPIs, particularly in vulnerable populations such as hospitalized patients or those with a history of recurrent C. difficile infections. The article advocates for a more judicious approach to PPI prescribing, with an awareness of the potential consequences on gut health and infection risk.

The article "The risks of long-term use of proton pump inhibitors: a critical review" by (Jaynes & B. Kumar, 2018) provides a comprehensive examination of the implications of prolonged proton pump inhibitor (PPI) usage, particularly in relation to Clostridium difficile infection (CDI). The authors elucidate several potential pathophysiologic mechanisms that may contribute to the increased risk of recurrent CDI associated with gastric acid suppression.

One of the key insights presented in the article is the impact of long-term PPI use on the colonic microbiome. The authors note that gastric acid suppression can significantly alter the microbial composition of the gut, leading to decreased colonization resistance. This alteration is critical, as a healthy and diverse microbiome plays a vital role in preventing the overgrowth of pathogenic organisms, including C. difficile. (Jaynes & B. Kumar, 2018) highlight that a small number of studies have documented a marked reduction in the diversity of the bacterial flora within just 30 days of initiating PPI therapy. This loss of microbial

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

diversity is a notable characteristic observed in patients suffering from CDI, suggesting a possible link between PPI use and the susceptibility to C. difficile proliferation.

Moreover, the article discusses how the diminished microbial diversity resulting from PPI use may facilitate the growth of C. difficile by eliminating nutrient competition within the gut. This perspective is particularly relevant in understanding the mechanisms behind recurrent CDI, as the competition for resources among gut bacteria is a critical factor in maintaining a balanced microbiome. The authors argue that the disruption of this balance through PPI-induced changes could create an environment conducive to CDI.

The article "Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment" by (Stuart Bradley et al., 2019) provides a critical examination of the relationship between proton pump inhibitors (PPIs) and outcomes in elderly patients following Clostridium difficile infection (CDI) treatment. The authors highlight the significant burden of CDI, particularly among vulnerable populations such as the elderly and those in healthcare settings, with approximately 450,000 new cases reported annually in the United States.

The study is particularly relevant given the increasing use of PPIs in hospitalized patients, which the authors suggest may contribute to heightened risks of both initial and recurrent CDI. The article presents a thorough cohort analysis, tracking patients over a six-month period post-treatment to evaluate the correlation between PPI exposure and mortality outcomes. This longitudinal approach allows for a comprehensive assessment of the implications of PPI use in the context of CDI, addressing a gap in existing literature regarding the long-term effects of acid suppression therapy.

(Stuart Bradley et al., 2019) effectively synthesize previous research indicating that acid-reducing medications, including PPIs and histamine blockers, are associated with increased CDI risk. They also raise concerns about the potential complications arising from concurrent use of these medications during CDI treatment, which may exacerbate patient outcomes. The authors' findings suggest that PPI exposure is linked to higher mortality rates within the 180-day post-

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

treatment period, underscoring the importance of judicious use of these medications in susceptible populations.

The article's strength lies in its rigorous methodology and the relevance of its findings to clinical practice. However, it also acknowledges the limitations inherent in observational studies, such as potential confounding factors that may influence mortality outcomes. The authors call for further research to clarify the causal mechanisms underlying the observed associations and to explore alternative strategies for managing acid suppression in patients at risk for CDI.

The article "Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection" by (Kachrimanidou & Tsintarakis, 2020) provides a comprehensive examination of the interplay between gastric acid suppression, particularly through the use of proton pump inhibitors (PPIs), and the incidence of recurrent Clostridium difficile infection (CDI). The authors effectively highlight the mechanisms by which PPIs may contribute to the pathogenesis of CDI through alterations in gut microbiota composition.

One of the key insights from the article is the role of PPIs in increasing gastric pH, which subsequently decreases the colonization resistance against C. difficile. This is particularly significant as the authors note that a higher gastric pH can facilitate the survival and proliferation of C. difficile spores in the gastrointestinal tract. The disruption of the gut microbiota caused by PPIs, especially when combined with antibiotic therapy, is a critical factor associated with the development of CDI. The article emphasizes that the use of PPIs leads to a distinct shift in microbial populations, characterized by a decrease in beneficial Lactobacillus species and a relative increase in Firmicutes, alongside a decrease in Bacteroidetes. This shift in the Firmicutes to Bacteroidetes ratio is posited as a potential predisposing factor for CDI, underscoring the importance of maintaining microbial diversity in gut health.

Moreover, the authors draw attention to the specific vulnerabilities of patients with inflammatory bowel disease (IBD), who exhibit reduced microbial diversity and an increased presence of pathogenic bacteria, such as Proteobacteria. The article presents compelling evidence that individuals with IBD not only have a

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

higher risk of developing CDI but also experience worse outcomes and higher recurrence rates. This connection between IBD, altered gut microbiota, and CDI recurrence is particularly relevant for clinicians managing patients with gastrointestinal disorders.

The critical evaluation of the material reveals that while the article provides substantial insights into the relationship between gastric acid suppression and CDI, it would benefit from a more extensive discussion on potential clinical implications and management strategies for patients at risk. The authors could also explore the impact of alternative treatments for gastrointestinal conditions that do not carry the same risks associated with PPIs.

The article "Association Between Risk of Clostridium difficile Infection and Duration of Proton Pump Inhibitor or H2-Receptor Antagonist Use in Hospitalized Patients" by (Huang et al., 2024) presents a comprehensive examination of the relationship between gastric acid suppression and the incidence of recurrent Clostridium difficile infection (CDI). The authors employ a systematic review and meta-analysis approach to synthesize existing literature, focusing on the comparative risks associated with proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs).

The main findings of the study underscore a significant positive correlation between the use of PPIs and the risk of CDI, particularly in hospitalized patients. This association is critical, as it suggests that the pharmacological suppression of gastric acid may disrupt the gastrointestinal microbiome, thereby creating an environment conducive to CDI proliferation (Huang et al., 2024). The article meticulously details the mechanisms by which PPIs may contribute to this increased risk, including alterations in gastric pH that facilitate the survival and colonization of C. difficile spores.

Furthermore, the authors differentiate the risks posed by PPIs and H2RAs, revealing that while both classes of medications are associated with increased CDI risk, PPIs exhibit a more pronounced effect. This distinction is particularly relevant for clinical practice, as it may guide healthcare providers in prescribing practices,

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

especially for patients with a history of CDI or those at heightened risk for recurrent infections (Huang et al., 2024).

The systematic review aspect of the article is robust, as it incorporates a 15-year hospital cohort study, providing a solid empirical foundation for the conclusions drawn. The authors effectively highlight the need for cautious use of gastric acid suppressants, advocating for a balanced approach that weighs the benefits of acid suppression against the potential risk of CDI.

CONCLUSION

The body of literature concerning the association between gastric acid suppression, particularly through the use of proton pump inhibitors (PPIs), and recurrent Clostridium difficile infection (CDI) reveals a multifaceted relationship characterized by both potential risks and the need for careful clinical consideration. Several studies have highlighted the increasing prevalence of CDI, linking it to the rising use of PPIs, which alter the acidic environment of the stomach and may inadvertently facilitate the growth of C. difficile (M. Tleyjeh et al., 2012); (Patil & Blankenship, 2013). The systematic review by (M. Tleyjeh et al., 2012) emphasizes the need for a thorough evaluation of PPI use, particularly in vulnerable populations, while noting that the protective role of gastric acid against CDI may be compromised by acid-suppressive therapies.

Research conducted by (Jaynes & B. Kumar, 2018) and (Kachrimanidou & Tsintarakis, 2020) further elucidates the impact of PPIs on gut microbiota, revealing that long-term use can diminish microbial diversity, thereby reducing colonization resistance against C. difficile and increasing susceptibility to recurrent infections. Additionally, the analysis by (Weiss et al., 2015) illustrates how PPI use correlates with treatment outcomes for CDI, indicating that prolonged use can exacerbate the severity of the disease.

Conversely, some articles, such as the one by (Novack et al., 2014), challenge the direct causality between PPI use and CDI risk, suggesting that observational studies may be biased and that confounding factors, particularly antibiotic use, should not be overlooked in this context. This perspective calls for a

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

nuanced understanding of the interplay between gastric acid suppression and CDI, as other factors may significantly contribute to the observed associations.

The implications of PPI use extend beyond infection risk; studies like that of (Stuart Bradley et al., 2019) indicate that PPI exposure may also influence mortality rates among elderly patients post-CDI treatment, further complicating the clinical landscape. The systematic review by (Huang et al., 2024) reinforces the notion that both PPIs and H2-receptor antagonists are linked to increased CDI risk, particularly emphasizing the importance of duration of use in hospitalized patients.

In conclusion, the literature collectively underscores the critical need for healthcare providers to carefully weigh the benefits of PPI therapy against the potential risks of CDI, particularly in populations at heightened risk. The association between gastric acid suppression and CDI is complex, necessitating further research to elucidate the underlying mechanisms and to develop informed prescribing practices.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. M. Tleyjeh, I., A. Bin Abdulhak, A., Riaz, M., A. Alasmari, F., A. Garbati, M., AlGhamdi, M., Rahman Khan, A., Al Tannir, M., J. Erwin, P., Ibrahim, T., AlLehibi, A., M. Baddour, L., & J. Sutton, A., 2012. Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis. ncbi.nlm.nih.gov

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved

2. Patil, R. & Blankenship, L. A., 2013. Proton Pump Inhibitors and Clostridium Difficile Infection: Are We Propagating an Already Rapidly Growing Healthcare Problem?. ncbi.nlm.nih.gov
3. Novack, L., Kogan, S., Gimpelevich, L., Howell, M., Borer, A., P. Kelly, C., A. Leffler, D., & Novack, V., 2014. Acid Suppression Therapy Does Not Predispose to Clostridium difficile Infection: The Case of the Potential Bias. [PDF]
4. Weiss, K., Louie, T., A Miller, M., Mullane, K., W Crook, D., & L Gorbach, S., 2015. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. ncbi.nlm.nih.gov
5. Jaynes, M. & B. Kumar, A., 2018. The risks of long-term use of proton pump inhibitors: a critical review. ncbi.nlm.nih.gov
6. Stuart Bradley, E., Howe, E., Wu, X., & P. Haran, J., 2019. Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment. ncbi.nlm.nih.gov
7. Kachrimanidou, M. & Tsintarakis, E., 2020. Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection. ncbi.nlm.nih.gov
8. Huang, C. H., Tseng, Y. H., Tsai, W. S., Su, C. C., Cheng, C. L., Kao Yang, Y. H., Chang, Y. C., & Liu, Y. H., 2024. Association Between Risk of Clostridium difficile Infection and Duration of Proton Pump Inhibitor or H2-Receptor Antagonist Use in Hospitalized Patients. ncbi.nlm.nih.gov

Downloaded from theInternationalmedicaljournal.org. For personal use only. No other uses without permission.
Copyright © International Medical Journal Corp. Ltd. All rights reserved